SCHEDULE: PNC Financial Services Discloses Stake in Cadrenal Therapeutics

The PNC Financial Services Group, Inc. has filed a Schedule 13G, reporting beneficial ownership of 8.13% of Cadrenal Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• The PNC Financial Services Group, Inc. (PNC) has filed a Schedule 13G, indicating its beneficial ownership of Cadrenal Therapeutics, Inc. common stock.
• As of June 30, 2026, PNC beneficially owns 233,219 shares, representing 8.13% of the class of securities.
• PNC has sole voting power and sole dispositive power over these shares.
• The shares are held in a fiduciary capacity by PNC Bank, National Association for a client named Daniel Maltz, who has the right to receive or direct the sale of the securities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on beneficial ownership changes rather than operational or financial performance.

Positives

• PNC Financial Services Group, Inc. has disclosed its significant beneficial ownership stake, providing transparency to the market.
• The filing confirms a substantial holding (8.13%) in Cadrenal Therapeutics, Inc., which could indicate confidence or a strategic position.

Negatives

• The filing does not provide any operational or financial performance data for Cadrenal Therapeutics, Inc., limiting insight into the company's health.
• The beneficial ownership is held for a client (Daniel Maltz), meaning PNC's direct investment strategy is not fully represented by this filing alone.

Risks

• The filing does not explicitly mention any risks associated with Cadrenal Therapeutics, Inc. or the ownership stake.
• Potential market volatility for Cadrenal Therapeutics, Inc. stock could impact the value of the beneficial ownership.

Future Outlook

This filing is a Schedule 13G and does not contain forward-looking statements or guidance regarding Cadrenal Therapeutics, Inc.'s future performance.

Management Comments

• Gregory H. Kozich, Senior Vice President & Controller of The PNC Financial Services Group, Inc., certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and indicate passive ownership stakes. The 8.13% stake by PNC suggests a notable position in Cadrenal Therapeutics, Inc., a company likely operating in the biotechnology or pharmaceutical sector, though specific industry context for Cadrenal is not detailed in this filing.

Comparison to Industry Standards

• This filing is a standard Schedule 13G disclosure for beneficial ownership, which is a common regulatory requirement for significant stakes in publicly traded companies.
• The 8.13% ownership threshold is substantial for a passive investor and often triggers such filings, aligning with typical institutional investor reporting practices.

Related Party Transactions

• The securities are held in a fiduciary capacity by PNC Bank, National Association for client Daniel Maltz, who has the right to receive dividends or proceeds from sale, indicating a related party relationship in the context of beneficial ownership.

Stakeholder Impact

• Shareholders of Cadrenal Therapeutics, Inc. are informed of a significant beneficial owner, providing transparency.
• The client, Daniel Maltz, is the ultimate beneficiary of the shares and has control over dividends and sale proceeds.

Next Steps

• PNC Financial Services Group, Inc. will continue to hold the shares in a fiduciary capacity for its client.
• Further filings may be required if PNC's beneficial ownership percentage changes significantly.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Cadrenal Therapeutics, PNC Financial Services, common stock, fiduciary capacity, Daniel Maltz